The basic biology of PP2A in hematologic cells and malignancies

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Haesen, Dorien ^a   Sents, Ward ^a   Lemaire, Katleen ^b   Hoorne, Yana ^a   Janssens, Veerle ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Inhibitor; PP2A; PP2A activating drugs; Subunit; Tumor suppressor reactivation therapy

Indexed keywords

FINGOLIMOD; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

B CELL LYMPHOMA; BLOOD CELL; BONE MARROW; BRAIN CORTEX; CANCER INHIBITION; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELLULAR STRESS SIGNAL; CHRONIC MYELOID LEUKEMIA; DNA MICROARRAY; DRUG SELECTIVITY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMOGENESIS; MICROARRAY ANALYSIS; MRNA EXPRESSION ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; SPLEEN; THYMUS; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84915763090     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00347     Document Type: Review

References (150)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (2002) 298:1912-34.
2. Hunter T. Why nature chose phosphate to modify proteins. Philos Trans R Soc Lond B Biol Sci. (2012) 367:2513-6.
3. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9:28-39.
4. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. (2014) 89:547-56.
5. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 10:130-7.
6. Brautigan DL. Protein Ser/Thr phosphatases: the ugly ducklings of cell signalling. FEBS J. (2013) 280:324-45.
7. Tonks NK. Protein tyrosine phosphatases: from housekeeping enzymes to master regulators of signal transduction. FEBS J. (2013) 280:346-78.
8. Julien SG, Dubé N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer (2011) 11:35-49.
9. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev. (2008) 27:159-68.
10. Vintonyak VV, Antonchick AP, Rauh D, Waldmann H. The therapeutic potential of phosphatase inhibitors. Curr Opin Chem Biol. (2009) 13:272-83.
11. McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol. (2009) 75:1249-61.
12. De Munter S, Köhn M, Bollen M. Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chem Biol. (2013) 8:36-45.
13. Zhang M, Yogesha SD, Mayfield JE, Gill GN, Zhang Y. Viewing serine/threonine protein phosphatases through the eyes of drug designers. FEBS J. (2013) 280:4739-60.
14. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. (2005) 15:34-41.
15. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. (2008) 14:152-60.
16. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2009) 1795:1-15.
17. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. (2013) 14:e229-38.
18. Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem. (2011) 11:38-46.
19. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 353:417-39.
20. Lambrecht C, Haesen D, Sents W, Ivanova E, Janssens V. Structure, regulation, and pharmacological modulation of PP2A phosphatases. Methods Mol Biol (2013) 1053:283-305.
21. Slupe AM, Merrill RA, Strack S. Determinants for Substrate Specificity of Protein Phosphatase 2A. Enzyme Res (2011) 2011:398751.
22. Götz J, Probst A, Ehler E, Hemmings B, Kues W. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha. Proc Natl Acad Sci U S A. (1998) 95:12370-5.
23. Gu P, Qi X, Zhou Y, Wang Y, Gao X. Generation of Ppp2Ca and Ppp2Cb conditional null alleles in mouse. Genesis (2012) 50:429-36.
24. Zhou J, Pham HT, Ruediger R, Walter G. Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: differences in expression, subunit interaction, and evolution. Biochem J. (2003) 369:387-98.
25. Sablina AA, Hahn WC. The role of PP2A A subunits in tumor suppression. Cell Adh Migr. (2007) 1:140-1.
26. Kremmer E, Ohst K, Kiefer J, Brewis N, Walter G. Separation of PP2A core enzyme and holoenzyme with monoclonal antibodies against the regulatory A subunit: abundant expression of both forms in cells. Mol Cell Biol. (1997) 17:1692-701.
27. Janssens V, Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med. (2012) 12:268-87.
28. Kolupaeva V, Janssens V. PP1 and PP2A phosphatases: cooperating partners in modulating retinoblastoma protein activation. FEBS J. (2013) 280:627-43.
29. Hunt T. On the regulation of protein phosphatase 2A and its role in controlling entry into and exit from mitosis. Adv Biol Regul. (2013) 53:173-8.
30. Sontag JM, Sontag E. Regulation of cell adhesion by PP2A and SV40 small tumor antigen: an important link to cell transformation. Cell Mol Life Sci. (2006) 63:2979-91.
31. Reid MA, Kong M. Adaptation to metabolic stress: insights into a paradoxical Q. Cell Cycle (2013) 12:1807-8.
32. Kowluru A, Matti A. Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes: potential mechanisms and functional consequences. Biochem Pharmacol. (2012) 84:591-7.
33. Haesen D, Sents W, Ivanova E, Lambrecht C, Janssens V. Cellular inhibitors of Protein Phosphatase PP2A in cancer. Biomed Res-India (2012) 23:197-211.
34. Batut J, Schmierer B, Cao J, Raftery LA, Hill CS, Howell M. Two highly related regulatory subunits of PP2A exert opposite effects on TGF-beta/Activin/Nodal signalling. Development (2008) 135:2927-37.
35. Cegielska A1, Shaffer S, Derua R, Goris J, Virshup DM. Different oligomeric forms of protein phosphatase 2A activate and inhibit simian virus 40 DNA replication. Mol Cell Biol. (1994) 14:4616-23.
36. Ahn JH, McAvoy T, Rakhilin SV, Nishi A, Greengard P, Nairn AC. Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci U S A. (2007) 104:2979-84.
37. Ahn JH, Sung JY, McAvoy T, Nishi A, Janssens V, Goris J, et al. The B''/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc Natl Acad Sci U S A. (2007) 104:9876-81.
38. Foley EA, Maldonado M, Kapoor TM. Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase. Nat Cell Biol. (2011) 13:1265-71.
39. Louis JV, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S, et al. Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A. (2011) 108:6957-62.
40. Varadkar P, Despres D, Kraman M, Lozier J, Phadke A, Nagaraju K, et al. The protein phosphatase 2A B56γ regulatory subunit is required for heart development. Dev Dyn. (2014) 243:778-90.
41. Ruediger R, Ruiz J, Walter G. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol. (2011) 31:3832-44.
42. Strack S, Zaucha JA, Ebner FF, Colbran RJ, Wadzinski BE. Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits. J Comp Neurol. (1998) 392:515-27.
43. Zwaenepoel K, Louis JV, Goris J, Janssens V. Diversity in genomic organisation, developmental regulation and distribution of the murine PR72/B" subunits of protein phosphatase 2A. BMC Genomics (2008) 9:393.
44. Kong M, Ditsworth D, Lindsten T, Thompson CB. Alpha4 is an essential regulator of PP2A phosphatase activity. Mol Cell (2009) 36:51-60.
45. Jiang L, Stanevich V, Satyshur KA, Kong M, Watkins GR, Wadzinski BE, et al. Structural basis of protein phosphatase 2A stable latency. Nat Commun. (2013) 4:1699.
46. Sents W, Ivanova E, Lambrecht C, Haesen D, Janssens V. The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity. FEBS J. (2013) 280:644-61.
47. Wepf A, Glatter T, Schmidt A, Aebersold R, Gstaiger M. Quantitative interaction proteomics using mass spectrometry. Nat Methods (2009) 6:203-5.
48. Longin S, Jordens J, Martens E, Stevens I, Janssens V, Rondelez E, et al. An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem J. (2004) 380:111-9.
49. Chen LP, Lai YD, Li DC, Zhu XN, Yang P, Li WX, et al. α4 is highly expressed in carcinogen-transformed human cells and primary human cancers. Oncogene (2011) 30:2943-53.
50. Sakashita S, Li D, Nashima N, Minami Y, Furuya S, Morishita Y, et al. Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance. Pathol Int. (2011) 61:130-7.
51. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2Amediated inactivation in human malignant glioma. Cancer Res. (2009) 69:2870-7.
52. Wandzioch E, Pusey M, Werda A, Bail S, Bhaskar A, Nestor M, et al. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells. Cancer Res (2014) Jun 13. pii: canres.3130.2013.
53. Fellner T, Lackner DH, Hombauer H, Piribauer P, Mudrak I, Zaragoza K, et al. A novel and essential mechanism determining specificity and activity of protein phosphatase 2A (PP2A) in vivo. Genes Dev. (2003) 17:2138-50.
54. Hombauer H, Weismann D, Mudrak I, Stanzel C, Fellner T, Lackner DH, et al. Generation of active protein phosphatase 2A is coupled to holoenzyme assembly. PLoS Biol. (2007) 5:e155.
55. Leulliot N, Vicentini G, Jordens J, Quevillon-Cheruel S, Schiltz M, Barford D, et al. Crystal structure of the PP2A phosphatase activator: implications for its PP2A-specific PPIase activity. Mol Cell (2006) 23:413-24.
56. Guo F, Stanevich V, Wlodarchak N, Sengupta R, Jiang L, Satyshur KA, et al. Structural basis of PP2A activation by PTPA, an ATP-dependent activation chaperone. Cell Res. (2014) 24:190-203.
57. De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, et al. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry (1999) 38:16539-47.
58. Ogris E, Du X, Nelson KC, Mak EK, Yu XX, Lane WS, et al. A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J Biol Chem. (1999) 274:14382-91.
59. Stanevich V, Jiang L, Satyshur KA, Li Y, Jeffrey PD, Li Z, et al. The structural basis for tight control of PP2A methylation and function by LCMT-1. Mol Cell (2011) 41:331-42.
60. Stanevich V, Zheng A, Guo F, Jiang L, Wlodarchak N, Xing Y. Mechanisms of the scaffold subunit in facilitating protein phosphatase 2A methylation. PLoS One (2014) 9:e86955.
61. Janssens V, Longin S, Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci. (2008) 33:113-21.
62. Kong M, Fox CJ, Mu J, Solt L, Xu A, Cinalli RM, et al. The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science (2004) 306:695-8.
63. Ortega-Gutiérrez S, Leung D, Ficarro S, Peters EC, Cravatt BF. Targeted disruption of the PME-1 gene causes loss of demethylated PP2A and perinatal lethality in mice. PLoS One (2008) 3:e2486.
64. Sents W and Janssens V: unpublished work
65. Lee JA, Pallas DC. Leucine carboxyl methyltransferase-1 is necessary for normal progression through mitosis in mammalian cells. J Biol Chem. (2007) 282:30974-84.
66. Li M, Guo H, Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry (1995) 34:1988-96.
67. Li M, Makkinje A, Damuni Z. Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry (1996) 35:6998-7002.
68. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. (1996) 271:11059-62.
69. Matilla A, Radrizzani M. The Anp32 family of proteins containing leucine-rich repeats. Cerebellum (2005) 4:7-18.
70. Reilly PT, Yu Y, Hamiche A, Wang L. Cracking the ANP32 whips: Important functions, unequal requirement, and hints at disease implications. Bioessays (2014) 36:1062-71.
71. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K. Functional domains of templateactivating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun. (1999) 259:471-5.
72. Yu LG, Packman LC, Weldon M, Hamlett J, Rhodes JM. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. J Biol Chem. (2004) 279:41377-83.
73. Adachi Y, Pavlakis GN, Copeland TD. Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia. FEBS Lett. (1994) 340:231-5.
74. Irie A, Harada K, Araki N, Nishimura Y. Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A. PLoS One (2012) 7:e51242.
75. Vasudevan NT, Mohan ML, Gupta MK, Hussain AK, Naga Prasad SV. Inhibition of protein phosphatase 2A activity by PI3Kγ regulates β-adrenergic receptor function. Mol Cell (2011) 41:636-48.
76. ten Klooster JP, Leeuwen Iv, Scheres N, Anthony EC, Hordijk PL. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J. (2007) 26:336-45.
77. Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H, et al. Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging (2013) 34:1748-58.
78. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. (2001) 276:43285-93.
79. Liu Z, Jang SW, Liu X, Cheng D, Peng J, Yepes M, et al. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol Cell (2008) 29:665-78.
80. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett. (2011) 585:2653-9.
81. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood (2010) 115:615-25.
82. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 8:355-68.
83. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC, et al. Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. Mol Cell Biochem. (2012) 363:65-74.
84. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene (2011) 30:2504-13.
85. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2008) 111:275-84.
86. Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood (2011) 118:4150-8
87. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. (2009) 23:751-63.
88. Al-Murrani SW, Woodgett JR, Damuni Z. Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J. (1999) 341:293-8.
89. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell (2007) 130:51-62.
90. Khanna A, Pimanda JE, Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res. (2013) 73:6548-53.
91. Ventelä S, Côme C, Mäkelä JA, Hobbs RM, Mannermaa L, Kallajoki M, et al. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PLoS One (2012) 7:e33209.
92. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One (2011) 6:e17979.
93. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYCdependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. (2009) 101:793-805.
94. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. (2013) 3:182-97.
95. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene (2010) 29:6257-66.
96. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-Bourgeois C, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell (2010) 40:863-76.
97. Kim JS, Kim EJ, Oh JS, Park IC, Hwang SG. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Cancer Res. (2013) 73:6667-78.
98. Jeong AL, Lee S, Park JS, Han S, Jang CY, Lim JS, et al. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. J Biol Chem. (2014) 289:28-40.
99. Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM, Jäättelä M. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol. (2014) 204:713-27.
100. Puustinen P, Jäättelä M. KIAA1524/CIP2A promotes cancer growth by coordinating the activities of MTORC1 and MYC. Autophagy (2014) 10:1352-4.
101. McConnell JL, Gomez RJ, McCorvey LR, Law BK, Wadzinski BE. Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway. Oncogene (2007) 26:6021-30.
102. Smetana JH, Zanchin NI. Interaction analysis of the heterotrimer formed by the phosphatase 2A catalytic subunit, alpha4 and the mammalian ortholog of yeast Tip41 (TIPRL). FEBS J. (2007) 274:5891-904.
103. Gingras AC, Caballero M, Zarske M, Sanchez A, Hazbun TR, Fields S, et al. A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity. Mol Cell Proteomics (2005) 4:1725-40.
104. Nakashima A, Tanimura-Ito K, Oshiro N, Eguchi S, Miyamoto T, Momonami A, et al. A positive role of mammalian Tip41-like protein, TIPRL, in the amino-acid dependent mTORC1-signaling pathway through interaction with PP2A. FEBS Lett. (2013) 587:2924-9.
105. Song IS, Jun SY, Na HJ, Kim HT, Jung SY, Ha GH, et al. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis. Gastroenterology (2012) 143:1341-51.
106. Mochida S, Maslen SL, Skehel M, Hunt T. Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science (2010) 330:1670-3.
107. Gharbi-Ayachi A, Labbé JC, Burgess A, Vigneron S, Strub JM, Brioudes E, et al. The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science (2010) 330:1673-7.
108. Manchado E, Guillamot M, de Cárcer G, Eguren M, Trickey M, García-Higuera I, et al. Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. Cancer Cell (2010) 18:641-54.
109. Mochida S. Regulation of α-endosulfine, an inhibitor of protein phosphatase 2A, by multisite phosphorylation. FEBS J. (2014) 281:1159-69.
110. Okumura E, Morita A, Wakai M, Mochida S, Hara M, Kishimoto T. Cyclin B-Cdk1 inhibits protein phosphatase PP2A-B55 via a Greatwall kinase-independent mechanism. J Cell Biol. (2014) 204:881-9.
111. Dupré A, Daldello EM, Nairn AC, Jessus C, Haccard O. Phosphorylation of ARPP19 by protein kinase A prevents meiosis resumption in Xenopus oocytes. Nat Commun. (2014) 5:3318.
112. Porter IM, Schleicher K, Porter M, Swedlow JR. Bod1 regulates protein phosphatase 2A at mitotic kinetochores. Nat Commun. (2013) 4:2677.
113. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. (2010) 70:5438-47.
114. Esplin ED, Ramos P, Martinez B, Tomlinson GE, Mumby MC, Evans GA. The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer (2006) 45:182-90.
115. Zhu Y, Loukola A, Monni O, Kuokkanen K, Franssila K, Elonen E, et al. PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas. Leuk Lymphoma (2001) 41:177-83.
116. Kalla C, Scheuermann MO, Kube I, Schlotter M, Mertens D, Döhner H, et al. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer (2007) 43:1328-35.
117. Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia (2011) 25:606-14
118. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. (2009) 106:12974-9.
119. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, et al. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia (2011) 25:1711-7.
120. Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, et al. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta (2014) 1843:1969-77.
121. Cristóbal I, Cirauqui C, Castello-Cros R, Garcia-Orti L, Calasanz MJ, Odero MD. Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica (2013) 98:e103-4.
122. Fält S, Merup M, Gahrton G, Lambert B, Wennborg A. Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol. (2005) 33:883-93.
123. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol. (2010) 12:372-9.
124. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, Catchpoole D, et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics (2009) 4:185-93
125. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol. (2013) 88:16-23.
126. Kamada Y, Sakata-Yanagimoto M, Sanada M, Sato-Otsubo A, Enami T, Suzukawa K, et al. Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. Int J Hematol. (2012) 96:492-500.
127. Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, et al. KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. Leuk Res. (2011) 35:133-5.
128. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. (2011) 33:290-8.
129. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood (2011) 117:6660-8.
130. Wang J, Huang T, Sun J, Yu Y, Liu Z, Li W, et al. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. Med Oncol. (2014) 31:112.
131. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, et al. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica (2013) 98:729-38.
132. Lilja L, Haapasaari KM, Bloigu R, Salonen T, Ristimäki A, Turpeenniemi-Hujanen T, et al. Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma. Histopathology (2013) 63:438-9.
133. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. (2007) 117:2408-21.
134. Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica (2012) 97:543-50.
135. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drugresistant cells from chronic myelogenous leukemia patients. Oncogene (2009) 28:1669-81.
136. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. (2013) 45:18-24.
137. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol. (1992) 12:3346-55.
138. Rosati R, La Starza R, Barba G, Gorello P, Pierini V, Matteucci C, et al. Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. Haematologica (2007) 92:232-5.
139. Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, Macleod RA, et al. SETNUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. (2009) 2:3.
140. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 111:4668-80.
141. Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB, et al. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One (2012) 7:e36429
142. Yang Y, Huang Q, Lu Y, Li X, Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem. (2012) 113:1314-22.
143. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. (2013) 5:105-21.
144. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood (2013) 122:1923-34.
145. Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia (2014) 28:1915-8.
146. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F, et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol. (2011) 186:2535-42.
147. Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. (2014) 20:2092-103.
148. Fujiwara N, Kawasaki H, Yabe R, Christensen DJ, Vitek MP, Mizuno T, et al. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma. J Vet Med Sci. (2013) 75:349-54.
149. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest. (2014) 124:644-55.
150. Thorrez L, Laudadio I, Van Deun K, Quintens R, Hendrickx N, Granvik M, et al. Tissuespecific disallowance of housekeeping genes: the other face of cell differentiation. Genome Res. (2011) 21:95-105.